Recombinant activated factor VII in approved indications: Update on safety
نویسندگان
چکیده
منابع مشابه
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...
متن کاملImmunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats.
Recombinant activated factor VII (rFVIIa; NovoSeven) has been widely used to treat bleeding in patients with haemophilia with inhibitors. To increase the intrinsic activity, analogues of rFVIIa (rFVIIa Q, rFVIIa DVQ, and rFVIIa DVQA) with altered amino acid sequence at or near the active centre have been developed. The immunogenicity of these analogues was tested in a rat immune tolerance model...
متن کاملThe role of recombinant activated factor VII in cardiac surgery
Recombinant factor VIIa may reduce surgical blood loss and transfusion of blood products in cardiac surgery. However, the true risks of its use in this setting remains to be elucidated, especially when it is administered with other potent pro-haemostatic agents. We reviewed the recent literature on this topic and suggest that the off label use of recombinant factor VIIa is likely to continue. I...
متن کاملUse of recombinant activated factor VII in trauma
In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conduct...
متن کاملevaluation of aryoseven safety (recombinant activated factor vii) in patients with bleeding disorders (an observational post-marketing surveillance study)
background: recombinant activated factor vii induces hemostasis in patients with coagulopathy disorders. aryoseven™ as a safe iranian recombinant activated factor vii has been available on our market. this study was performed to establish the safety of aryoseven on patients with coagulopathy disorder. methods: this single-center, descriptive, cross sectional study was carried out in thrombus an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haemophilia
سال: 2018
ISSN: 1351-8216
DOI: 10.1111/hae.13547